Combination therapy options in stable COPD

U.S. Pharmacist

Volumn 35, Issue 7, 2010, Pages 31-37

  Choo, Christie ^a,b  

^a ST JOHN'S UNIVERSITY   (United States)

^b NEW YORK PRESBYTERIAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; BETA 2 ADRENERGIC RECEPTOR; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CHOLINERGIC RECEPTOR; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; FORMOTEROL; GLUCOCORTICOID RECEPTOR; INFLUENZA VACCINE; IPRATROPIUM BROMIDE; IPRATROPIUM BROMIDE PLUS SALBUTAMOL SULFATE; MUSCARINIC RECEPTOR; MUSCARINIC RECEPTOR BLOCKING AGENT; PNEUMOCOCCUS VACCINE; SALBUTAMOL; SALMETEROL; TIOTROPIUM BROMIDE;

ADD ON THERAPY; BLURRED VISION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CLOSED ANGLE GLAUCOMA; CORTICOSTEROID THERAPY; COUGHING; DIZZINESS; DRUG DOSE INCREASE; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG SELECTIVITY; DRUG TARGETING; DYSPHONIA; HEART PALPITATION; HUMAN; INFLAMMATION; LYMPHOCYTIC INFILTRATION; MACROPHAGE; MORNING DOSAGE; NEUTROPHIL; OXYGEN THERAPY; PNEUMONIA; PRACTICE GUIDELINE; RECEPTOR BLOCKING; REVIEW; RHINOPHARYNGITIS; SORE THROAT; T LYMPHOCYTE; TACHYCARDIA; THROAT IRRITATION; THRUSH; TREMOR; URINE RETENTION; VACCINATION; XEROSTOMIA;

EID: 77955728937     PISSN: 01484818     EISSN: None     Source Type: Trade Journal    
DOI: None     Document Type: Review

References (29)

1. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med. 2007;176:532-555. (Pubitemid 47403272)
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Updated December 2009. www.goldcopd.com. Accessed April 16, 2010.
3. Cazzola M, Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther. 2010;23:257-267.
4. Hattotuwa KL, Gizycki MJ, Ansari TW, et al. The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med. 2002;165:1592-1596. (Pubitemid 34693937)
5. Roth M, Johnson PR, Rudiger JJ, et al. Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signaling. Lancet. 2002;360:1293-1299. (Pubitemid 35284621)
6. Restrepo RD. A stepwise approach to management of stable COPD with inhaled pharmacotherapy: a review. Respir Care. 2009;54:1058-1081.
7. Thomason MJ, Strachan DP. Which spirometric indices best predict death from chronic obstructive pulmonary disease? Thorax. 2000;55:785-788.
8. Dorinsky PM, Reisner C, Ferguson GT, et al. The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD. Chest. 1999;115:966-971. (Pubitemid 29193662)
9. COMBIVENT Inhalation Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. An 85-day multicenter trial. Chest. 1994;105:1411-1419.
10. Levin DC, Little KS, Laughlin KR, et al. Addition of anticholinergic solution prolongs bronchodilator effect of beta 2 agonists in patients with chronic obstructive pulmonary disease. Am J Med. 1996;100:40S-48S.
11. Friedman M, Serby CW, Menjoge SS, et al. Pharmacoeconomic evaluation of a combination of ipratropium plus albuterol compared with ipratropium alone and albuterol alone in COPD. Chest. 1999;115:635-641. (Pubitemid 29129937)
12. Welte T. Optimising treatment for COPD - new strategies for combination therapy. Int J Clin Pract. 2009;63:1136-1149.
13. van Noord JA, de Munck DR, Bantje TA, et al. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J. 2000;15:878-885. (Pubitemid 30321844)
14. Chapman KR, Arvidsson P, Chuchalin AG, et al. The addition of salmeterol 50 mg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Can Respir J. 2002;9:178-185. (Pubitemid 34863635)
15. D'Urzo AD, De Salvo MC, Ramirez-Rivera A, et al. In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: a 3-week, randomized, double-blind, within-patient, multicenter study. Chest. 2001;119:1347-1356. (Pubitemid 32686014)
16. Casaburi R, Conoscenti CS. Lung function improvements with once-daily tiotropium in chronic obstructive pulmonary disease. Am J Med. 2004;117(suppl 1):33S-40S.
17. Vincken W, van Noord JA, Greefhorst AP, et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J. 2002;19:209-216. (Pubitemid 34162819)
18. Tashkin D, Pearle J, Iezzoni D, Varghese ST. Formoterol and tiotropium compared with tiotropium alone for treatment of COPD. COPD. 2009;6:17-25.
19. Vogelmeier C, Kardos P, Harari S, et al. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med. 2008;102:1511-1520.
20. Aaron SD, Vandemheen KL, Fergusson D, et al; Canadian Thoracic Society/Canadian Respiratory Clinical Research Consortium. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146:545-555.
21. COMBIVENT Inhalation Solution Study Group. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest. 1997;112:1514-1521.
22. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med. 1999;340:1948-1953.
23. Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320:1297-1303.
24. Chung KF, Caramori G, Adcock IM. Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future. Eur J Clin Pharmacol. 2009;65:853-871.
25. Calverley PM, Anderson JA, Celli B, et al; TORCH Investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775-789. (Pubitemid 46294610)
26. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178:332-338.
27. Singh D, Brooks J, Hagan G, et al. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax. 2008;63:592-598. (Pubitemid 351969251)
28. Cazzola M, Andò F, Santus P, et al. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm Pharmacol Ther. 2007;20:556-561. (Pubitemid 47077647)
29. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in COPD patients. Am J Respir Crit Care Med. 2009;180:741-750.